accountovercame revenue lost to generic competition. Earnings excluding a $500 million charge to settle an arbitration dispute with Johnson & Johnson and other one-time items were 92 cents a share, beating the 84-cent average estimate of 15 analysts surveyed by...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Merck Profit Tops Analyst Estimates on Higher Drug Sales
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account